BDBM363292 3-((4-chloro-5-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-(((2-hydroxy-3-morpholinopropyl)amino)methyl)phenoxy)methyl)benzonitrile::US9850225, Example 1212
SMILES: Cc1c(COc2cc(OCc3cccc(c3)C#N)c(CNCC(O)CN3CCOCC3)cc2Cl)cccc1-c1ccc2OCCOc2c1
InChI Key: InChIKey=NSRCGMJSSNCAPQ-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Programmed cell death 1 ligand 1 (Homo sapiens (Human)) | BDBM363292 (3-((4-chloro-5-((3-(2,3-dihydrobenzo[b][1,4]dioxin...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company US Patent | Assay Description The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and... | US Patent US9850225 (2017) BindingDB Entry DOI: 10.7270/Q2N018TZ | |||||||||||
More data for this Ligand-Target Pair |